FibroGen (NASDAQ:FGEN) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of FibroGen (NASDAQ:FGEN) in a research report report published on Thursday,Benzinga reports. HC Wainwright currently has a $10.00 price objective on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the stock. William Blair reissued a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th. StockNews.com initiated coverage on shares of FibroGen in a research note on Thursday, February 13th. They issued a “hold” rating on the stock.

FibroGen Trading Up 37.4 %

Shares of FGEN stock opened at $0.77 on Thursday. FibroGen has a 1-year low of $0.18 and a 1-year high of $2.80. The stock has a market cap of $77.83 million, a price-to-earnings ratio of -0.63 and a beta of 0.75. The stock has a 50-day moving average of $0.52 and a 200-day moving average of $0.43.

Institutional Investors Weigh In On FibroGen

Several institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC increased its holdings in FibroGen by 3.1% in the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 32,884 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of FibroGen by 430.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after buying an additional 1,358,194 shares during the period. FMR LLC increased its stake in shares of FibroGen by 21.8% in the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 68,569 shares in the last quarter. Franklin Street Advisors Inc. NC lifted its position in shares of FibroGen by 100.0% during the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 100,000 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new position in shares of FibroGen during the 3rd quarter valued at $307,000. Institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.